Hofseth BioCare says ProGo trial lifts GLP-1 markers, lean muscle mass in overweight adults

• Hofseth BioCare published peer-reviewed results from a 56-day pilot trial of its ProGo salmon peptide supplement in Biomedicines.
• The randomized, double-blind study in overweight adults indicated broader improvements in metabolic health and healthy-aging markers versus a protein-matched whey comparator.
• Signals included better body composition with lean mass preservation, lower inflammation, improved glucose control, and stronger iron-status measures.
• The company framed the findings as preliminary due to the small sample size, pointing to the need for larger, longer, placebo-controlled studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hofseth BioCare ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270245OMX_____CNEWS_EN_GNW1001244509_en) on July 27, 2026, and is solely responsible for the information contained therein.